Clinical trials: Corneal Epithelial Defect
Limbal Stem Cell Deficiency
Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft
The main aim of the study is to determine the safety and feasibility of a cultivated autologous limbal epithelial cell (CALEC) transplantation in the treatment of limbal stem cell deficiency.
- Trial name
- CALEC (NCT02592330)
- Testing
- Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft, Cultivation of Limbal epithelial cells into a graft, CALEC Transplant
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Corneal Epithelial Defect
ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects in a Phase Ⅱ Clinical Trial
A multicenter, randomized, double-blind, placebo-controlled clinical trial was designed. The study included two experimental groups (low-dose ZKY001 eye drops group and medium-dose ZKY001 eye drops group) and a placebo control…
- Trial name
- NCT06213727
- Testing
- lowe-dose ZKY001 eye drops, Medium-dose ZKY001 eye drops, ZKY001 simulated eye drops
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Primary Pterygium
Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision
The purpose of this study is to determine whether there is a difference in corneal epithelial healing rate and/or toxicity following pterygium excision, between eyes treated post-operatively by moxifloxacin(VIGAMOX)versus…
- Trial name
- NCT00892918
- Testing
- Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3%
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Meir Medical Center
Persistent Epithelial Defect
A Study to Investigate the Safety and Clinical Effect of Nexagon® to Treat Persistent Epithelial Defects
The purpose of this study is to evaluate the efficacy and safety of Nexagon® in subjects with Persistent Epithelial Defects (PED) originally caused by chemical burns.
- Trial name
- NCT00821561
- Testing
- Nexagon®, Nexagon® vehicle
- Volunteers
- 90 people
- Sponsor
- OcuNexus Therapeutics, Inc.
Corneal Epithelial Defect
Treatment of PED With AMT and Autologous Serum
Patients with persistent corneal epithelial defects who have not responded to conventional therapy will be randomized to treatment with either amniotic membrane transplantation or autologous serum 20%.
- Trial name
- NCT00238862
- Testing
- Amniotic membrane transplantation, Autologous serum/BSS 20%
- Where
- Saudi Arabia
- Volunteers
- 180 people
- Sponsor
- King Khaled Eye Specialist Hospital
Persistent Corneal Epithelial Defect
A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects
The objective of this study is to evaluate the safety and effectiveness of topical KIO-201 in patients with persistent corneal epithelial defects (PED). KIO-201 will be administered six (6) times per day while awake for 4 weeks.
- Trial name
- NCT05436288
- Testing
- KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Kiora Pharmaceuticals, Inc.
Corneal Epithelial Defects After Ocular Surgeries
Topical Autologous Insulin Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries
Topical insulin application has been proved recently to increase corneal reepithelization rate over diabetic animals. However, its effectiveness on corneal epithelial wound healing in patients who received pars planar vitrectomy…
- Trial name
- NCT01031888
- Testing
- Topical insulin eye drops, Conventional postoperative eye drops
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- National Taiwan University Hospital
Persistent Corneal Epithelial Defects
Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects
The purpose of this study is to evaluate the efficacy and safety of Nexagon® in subjects with persistent corneal epithelial defects (PED) resulting from corneal epithelial debridement during diabetic vitrectomy surgery, HSV…
- Trial name
- NTX-PED-001 (NCT01165450)
- Testing
- Nexagon, Vehicle only
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco
Persistent Corneal Epithelial Defect
ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects
The primary objective is to determine the efficacy of ST266 eye drops in healing persistent epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers will enter into an additional 8-week…
- Trial name
- NCT05066698
- Testing
- ST266, 0.67% Sodium Chloride Ophthalmic Solution, Open-label ST266
- Where
- 31 sites in United States
- Volunteers
- 8 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Persistent Corneal Epithelial Defect
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
This is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of cenegermin in inducing complete epithelial healing in participants…
- Trial name
- NCT07519902
- Testing
- Cenegermin, Vehicle
- Where
- 77 sites in United States, Argentina and 12 more
- Volunteers
- 150 people
- Sponsor
- Dompé Farmaceutici S.p.A
Persistent Epithelial Defect
Autologous Platelet-rich Plasma in the Treatment of Persistent Epithelial Defects
Persistent epithelial defects (PED) are corneal ulcers that do not heal within the first two weeks of treatment with artificial tears or ocular lubricant ointment.
- Trial name
- NCT03653650
- Testing
- PRP plus BCL, BCL plus PFL, Eye patch plus ocular lubricant ointment
- Where
- Mexico
- Volunteers
- 54 people
- Sponsor
- Universidad Autonoma de Nuevo Leon
Corneal Diseases
Phase I Clinical Study of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defect
One dose group of 0.004% was used.
- Trial name
- NCT07132437
- Testing
- ZKY001 EYE DROPS
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Corneal Defect
Evaluating the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects
The subjects of this study were patients who underwent corneal endothelial transplantation,who were randomly divided into 3 groups, 2 groups (0.002% and 0.004% ZKY001 eye drops) and 1 placebo control group.
- Trial name
- NCT04228926
- Testing
- ZKY001 eye drops 0.3g:0.006mg, ZKY001 eye drops 0.3g:0.012mg, ZKY001 simulated eye drops
- Where
- China
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Postoperative Ocular Pain After PRK Surgery
Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery
The purpose of this study is to determine if SAF312 eye drops have an adequate safety and efficacy profile to justify further clinical development for the treatment of ocular pain associated with corneal epithelial defect such as…
- Trial name
- NCT02961062
- Testing
- SAF312
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Persistent Corneal Epithelial Defect
Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED
The primary objective of the study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagnosis of PCED.
- Trial name
- CHASE (NCT05727878)
- Testing
- KPI-012, KPI-012 Vehicle
- Where
- 46 sites in United States, Argentina and 1 more
- Volunteers
- 103 people
- Sponsor
- Combangio, Inc
Corneal Epithelial Defect
To Evaluate the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects Caused by Neurotrophic Keratitis
An investigator-initiated single-center, randomized, double-blind, placebo-controlled clinical study .The main purpose is to evaluate the effectiveness of ZKY001 eye drops in treating corneal epithelial defects caused by…
- Trial name
- NCT07120308
- Testing
- ZKY001 eye drops
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Neurotrophic Keratitis
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
The Sponsor is developing KB801, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human nerve growth factor (NGF) to the corneas of people…
- Trial name
- EMERALD-1 (NCT06999733)
- Testing
- KB801
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Krystal Biotech, Inc.
Persistent Corneal Epithelial Defect
ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects
The primary aim of the study is to evaluate the clinical response of ST266 treated subjects with persistent corneal epithelial defects during 28 days of therapy.
- Trial name
- NCT03687632
- Testing
- ST266
- Where
- 8 sites in United States
- Volunteers
- 13 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Corneal Persistent Epithelial Defect
NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries
This study will enroll participants with a non-infected, corneal persistent epithelial defect (PED) resulting from an ocular chemical and/or thermal ocular injury which is non-responsive or refractory to current standard of care…
- Trial name
- EXPEDE (NCT04081103)
- Testing
- Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Glaukos Corporation
Persistent Corneal Epithelial Defect
A Study to Evaluate the Efficacy and Safety of TP-06 for PCED
Capellion is a Phase 2 trial comparing TP-06 2.0% with Vehicle in up to 32 adults with persistent corneal epithelial defects. Participants will receive treatment for 8 weeks and be followed for 2 additional weeks to assess…
- Trial name
- Capellion (NCT07886268)
- Testing
- TP-06, Vehicle of TP-06
- Where
- 14 sites in United States, Dominican Republic and 2 more
- Volunteers
- 32 people
- Sponsor
- Tarsus Pharmaceuticals, Inc.